Regarding response to Narayanan et al's "Adverse events in cemiplimab therapy for locally advanced or metastatic cSCC: A global propensity-matched retrospective cohort study"
J Am Acad Dermatol. 2024 Nov 8:S0190-9622(24)03105-0.
doi: 10.1016/j.jaad.2024.10.059.
Online ahead of print.
1 Division of Dermatology, Baylor University Medical Center, Dallas, Texas.
2 Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, Texas.
3 Division of Dermatology, Baylor University Medical Center, Dallas, Texas; Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, Texas; Epiphany Dermatology, Dallas, Texas; Department of Dermatology, University of Texas at Southwestern, Dallas, Texas. Electronic address: Stan.tolkachjov@gmail.com.